Navigation Links
Watson Launches Generic AMRIX®
Date:5/16/2011

PARSIPPANY, N.J., May 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc.  AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Under the terms of the non-exclusive sales agent agreement, Anesta manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States on behalf of Anesta and will receive payments based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending March 31, 2011, AMRIX had sales of approximately $125 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.  

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

AMRIX® is a registered trademark of Cephalon, Inc.  CONTACTS: Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Concerta®
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
3. Watson First Quarter 2011 Net Revenue Increases to $877 Million
4. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
5. Watson Confirms Welchol® Patent Challenge
6. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
7. Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
8. Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
9. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
10. Watson Confirms OxyContin® Patent Challenge
11. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) ... Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... symptomatic relief of cough in adults and children 6 years ... ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... , Feb. 17, 2017  In partnership with ... for Good Health , The Jack Brewer Foundation ... with millions of dollars, worth of medicine to ... . IHI is a non-profit dedicated to treating chronic ... extremely active in Haiti and ...
(Date:2/17/2017)... NEW YORK , February 17, 2017 ... Composite and the S&P 500 edged lower at the ... its bullish streak above the 20,000 benchmark. Moreover, five ... bearish territories. Taking into consideration yesterday,s market sentiment, Stock-Callers.com ... morning: Smith & Nephew PLC (NYSE: SNN ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea ...
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Diego, CA (PRWEB) , ... February 17, 2017 ... ... initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively impact ... , “The Board of Trustees has long considered it our duty to seriously ...
Breaking Medicine News(10 mins):